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CASE DISCUSSION
A 5-year-old boy with WHO stage 3 HIV disease attends the 
Community Health Centre in Grabouw, approximately 100 km
from Tygerberg Academic Hospital. He has been on appropriate
doses for body weight of stavudine, lamivudine and efavirenz
for the past 14 months. At baseline his plasma HIV RNA was
87 000 copies per ml (log 4.94) and the CD4 count was 263/µl
(6.6%). He weighed 16 kg and his weight-for-age Z-score
(WAZ) was –0.69. He had just completed his second month of
antituberculosis (TB) therapy. TB was suspected because his
mother had TB and he had a persistent cough. 
Six months after starting HAART and 2 months after
completing anti-TB therapy:
■ The patient’s weight remained 16 kg.
■ Notably, he had features of chronic lung pathology and a
chest radiolograph showed generalised bronchiectasis.
■ He had no intercurrent illnesses.
■ He had attended the clinic for follow-up regularly, and
although there was no objective means of measuring this,
his compliance with medication (ART) seemed good and
his mother (a seasonal farm worker) confirmed this. His TB
treatment card showed good compliance with TB
treatment.
■ His viral load was undetectable.
■ His CD4 count was now 258/µl (0.36%).
■ A full blood count (FBC) and biochemistry (transaminases)
were normal.
Two months later, 8 months into highly active antiretroviral
therapy (HAART), the tests were repeated:
■ The patient had now lost a kilogram in body weight.
■ His mother reported that he had been admitted to the
regional hospital for 5 days for a ‘chest infection’. He had
received intravenous antibiotics but did not require
supplemental oxygen. There was no letter documenting
clinical findings, investigations or management during that
episode. 
■ He had no constitutional or pulmonary symptoms, and had
no excessive losses (e.g. diarrhoea). His appetite remained
good and his nutritional intake at home had not changed
in any form (he was also receiving nutritional supplements
from the clinic).
■ The only new finding was a crop of molluscum
contagiosum on his left lower eyelid.
■ On history, there were no known TB contacts in his
immediate environment.
■ The CD4 count was 181/µl (6.1%), and the total
lymphocyte count (TLC) 4 700 106 cells/l.
■ The viral load remained undetectable.
■ The rest of the FBC was normal.
At this time the patient was re-investigated for TB:
■ The tuberculin skin test was non-reactive
■ A sputum smear for acid-fast bacilli was negative and TB
cultures were negative after 42 days.
■ A chest radiograph showed no new changes.
Over the following few months his weight increased to 17 kg.
Treatment was adjusted to stavudine 20 mg capsules,
lamivudine 75 mg (half a tablet) twice daily and efavirenz 250
mg capsule at night (reduced as he was no longer receiving
rifampicin). His mother was shown how to use a pillbox in an
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The objective of antiretroviral therapy (ART) is to suppress viral replication so that immune restoration can occur. Failure of
immune restoration is usually associated with poor virological suppression. In children a good immunological and clinical
response to ART is often achieved despite incomplete viral suppression. However, we have recently managed a number of
children in whom immune restoration did not occur despite excellent virological suppression. We present a case, discuss
possible causes and speculate on the appropriate course of action.
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effort to assist with adherence to ART. Nutritional supplements
were provided in an effort to improve his nutritional status.
Four months after the last set of tests and 12 months into
HAART:
■ There are no new clinical symptoms or signs, and the
patient has had no serious illnesses during that period.
■ Compliance with clinic visits and medication (as well as
could be ascertained by means of pill counts and recall)
remained good, and his mother is concerned and
reasonably informed about his well-being and his CD4
count!
■ His weight is 17 kg (WAZ –1.07) and height 104 cm
(height-for-age Z-score –1.72, weight-for-height Z-score
0.09). 
■ The CD4 count is 164/µl (5.02%) and the TLC 5 900  106
cells/l.
■ The viral load is undetectable.
Table I shows these results in chronological order.
All the specimens were processed in the same laboratory, and
with the exception of baseline samples were all taken by the
same person.
Why is there no immunological recovery and worsening
immunosuppression after one year of ART, although there is
full viral suppression?
Why has the patient shown no improvement in growth at all?
POSSIBILITIES
■ We did not suspect hyperlactataemia/lactic acidosis, so
did not test for it. Also, the patient would need to travel
about 60 km to the centre where this can be done.
■ Does he have incompletely treated TB or resistant TB,
which is contributing to his state of persistent
immunosuppression? There is no evidence of radiological
deterioration and he remains asymptomatic
■ Does he have an occult opportunistic infection or
malignancy that is contributing to his immuno-
suppression? Which one? Where? Nothing is clinically
obvious. No palatal Kaposi’s sarcoma lesions were seen.
Mycobacterium avium-intracellulare infection is possible,
yet there is no focus of infection. He has remained on co-
trimoxazole throughout.
■ His total lymphocyte count has remained normal. What’s
going on?
Where, oh where, have his soldiers gone?
DISCUSSION
This case illustrates the problem of discordant
immunological and virological response to ART in a child.
After 12 months he has shown a good virological response.
Clinical response has been moderate. He has had no
significant weight gain, but there have been no significant
intercurrent illnesses. His CD4 count has declined persistently
and significantly.
The usual response to HAART is viral suppression and immune
reconstitution. Some patients, however, show discordance
between virological and immunological responses. In children,
a rise in the CD4 count despite detectable plasma HIV RNA
occurs fairly commonly. The converse, virological response and
the absence of immunological response, as in our patient, has
been described in adults. Poor CD4 responses can occur with
previous therapeutic failure, low baseline CD4+ T cells,
advanced disease, poor adherence to HAART, long duration of
therapy, and previous treatment interruption. So far there is
no evidence that patient age or viral or genetic factors are
implicated.1
Jevtovic and colleagues2 in Serbia recently conducted a
retrospective survey of discrepant values in a cohort of 446
adult patients.  Almost half showed dissociation, with 39% not
reaching a CD4 count of 400 cells/µl and 11% not reaching a
count of 200 despite adequate viral suppression. The most
important risk factor was a baseline CD4 count below 100/µl.
They did not associate discordant results with adverse
outcome. Protease inhibitors appeared to be protective, as they
prevent CD4 loss through inhibition of apoptosis of CD4 cells.3
The situation in Serbia is analogous to that in South Africa
where until recently lack of access to health care has resulted
in initiating ART in patients with advanced disease, as
described in the above case report.
As a means of evaluation, we ask and attempt to answer a
series of questions about this case.
WHAT COULD ACCOUNT FOR SUCH A RESPONSE?
1. Poor adherence to HAART seems an unlikely cause. We
think that the patient would not have achieved viral
suppression if he had not been receiving his therapy.
2. Is his immunological response to HAART perhaps simply
slow or delayed? This is uncommon in children, who in
contrast to adults usually have good CD4 recovery in the
face of incomplete viral suppression, with their thymic
response and naïve T-cell recovery rate being 10 - 40 times
Date Viral load CD4 TLC Weight WAZ
(copies (cells/µl) ( 106) (kg)
per ml) cells/l
Baseline 87 000 263 – 16 kg –0.69
(log 4.94) (6.6%) -
6/12 Undetectable 258 - 16 kg –1.13
(6.4%)
8/12 Undetectable 181 4 700 15 kg –1.29
(6.1%)
12/12 Undetectable 164 5 900 17 kg –1.07
(5.0%)
TABLE I. LABORATORY AND ANTHROPOMETRIC RESULTS
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faster than that of adults in the second phase of immune
restoration.4 However, responses to ART show individual
variation. In older children and those with baseline CD4%
significantly below 10%, immunological recovery on
HAART can be slow. Individuals who do not experience
significant increases in CD4 cell levels may have initiated
therapy after significant destruction to the thymus had
already occurred.
3. Is the patient harbouring an occult opportunistic infection,
leading to ongoing immune activation and thus poor
clinical and immunological response? He was re-inves-
tigated for TB to exclude the possibility of incompletely
treated or resistant TB. Another consideration was atypical
mycobacterial infection, particularly M. avium complex
(MAC). So far three sputa remain negative by smear and
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suppressive drugs have caused disturbance of bone
marrow T-cell progenitor production? If so, why would it
be a selective lymphocyte problem? There seems to be no
evidence of myelosuppression; all the patient’s blood cell
indices, including his total lymphocyte count, were in the
normal range. We did not ascertain whether the
lymphocytes were T or B cells. If they are primarily B cells,
it could mean that the thymus is severely impaired by HIV.
The combination of tenofovir and didanosine has been
associated with poor CD4 response but resolves with dose
reduction of TFV. We are unaware of this type of response
to other antiretrovirals.6
With no clear answers for the cause of this discordant
response, we speculate on management options.
COULD THERE BE AN IMMUNOLOGICAL REASON?
It would seem that the patient has good HIV-specific immune
responses, in that he has managed to suppress HIV replication
to undetectable levels. He would probably then be a candidate
for agents that enhance general immune activity, particularly
those that induce T-lymphocyte differentiation and stimulate
function, for example recombinant cytokines: interferon alpha
(IFN), particularly pegylated IFN alpha-2, tumour necrosis
factor (TNF) and interleukin-2 (IL-2). Cytokine dysregulation
has been described in HIV-infected patients. Diminished IL-2
receptors on CD4 cells were described in 1991.7 IL-2, a cytokine
that stimulates the production of CD4 cells, has been proposed
for patients who are unable to replenish CD4 cells, despite
adequate viral suppression on HAART.8 A number of trials have
shown improvement in CD4 responses in adults with mild
immunosuppression.9 A possible mechanism for this response
could be a diminished loss of CD4 cells through apoptosis.10
In anticipation of specific therapy, we continue to monitor the
patient and seek to optimise his care.
WHAT CAN WE DO?
Immediate strategies that could help are to improve
pulmonary care through physiotherapy, suppressive
antibiotics, and excluding
gastro-oesophageal reflux.
This will reduce pulmonary
inflammation and potential
loss of activated CD4 cells in
the lung. We will re-
evaluate for reactive
airways disease, where
inhaled steroids may be very
helpful. We will also
consider switching from
efavirenz to a protease
inhibitor in the hope of
diminishing CD4 apoptosis.
A single drug switch is
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